When NRAS and ASXL1 are double mutated, AML cells also hyperactivate the MEK/ERK/AP-1 signaling pathway, leading to the upregulation of AP-1-related genes and inhibitory immune checkpoint ligands PD-L2, CD80, CD86, and CD155. Here, NRAS is linked to acute myeloid leukemia.